25 results on '"Lacasce, A. S."'
Search Results
2. MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA
3. BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH STAGE III OR IV HODGKIN LYMPHOMA: A SUBGROUP ANALYSIS FROM THE PHASE 3 ECHELON‐1 STUDY
4. CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL)
5. Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB /Alliance 50403
6. Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
7. Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease
8. Current considerations in AYA Hodgkin lymphoma
9. Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation
10. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma
11. Non‐Hodgkin's Lymphoma
12. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma
13. Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project
14. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma
15. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network
16. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database
17. Improving the quality of bone marrow assessment
18. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab
19. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma
20. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era
21. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era
22. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma
23. Surveillance imaging of Hodgkin lymphoma patients in first remission
24. Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database
25. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.